Related Experiment Video

Updated: Feb 1, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

14.6K

[Renin-angiotensin system (RAS) as new molecular therapeutic targets in prostate cancer]

Yoshinobu Kubota1, Hiroji Uemura

  • 1Department of Urology, Yokohama City University Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 28, 2012
PubMed

Insights

The renin-angiotensin system (RAS) and AT1 receptor may drive prostate cancer growth. Angiotensin Receptor Blockers (ARBs) inhibited cancer cell proliferation and angiogenesis, suggesting their potential as targeted therapies for castration-resistant prostate cancer (CRPC).

Area of Science:

  • Oncology
  • Cardiovascular Research
  • Urology

Context:

  • Prostate cancer, particularly castration-resistant prostate cancer (CRPC), presents significant treatment challenges.
  • The role of the local renin-angiotensin system (RAS) in prostate cancer progression is increasingly recognized.
  • Androgen independence in prostate cancer suggests alternative growth pathways.

Purpose:

  • To investigate the involvement of Angiotensin II and its AT1 receptor in the growth of androgen-independent prostate cancer.
  • To evaluate the efficacy of Angiotensin Receptor Blockers (ARBs) in inhibiting prostate cancer cell proliferation and angiogenesis.
  • To assess the clinical benefit of ARBs in patients with castration-resistant prostate cancer (CRPC).

Summary:

  • Higher expression of the AT1 receptor was observed in prostate cancer tissue compared to normal tissue.
  • Angiotensin II was found to directly and indirectly stimulate prostate cancer cells, stromal cells, and angiogenic cells.
  • ARBs demonstrated inhibition of cancer cell proliferation and angiogenesis in experimental models.
  • Clinical administration of ARBs in CRPC patients led to decreased serum prostate-specific antigen (PSA) and improved performance status, especially in cachectic patients.

Impact:

  • These findings support the existence of an intrinsic RAS within the prostate gland.
  • ARBs show promise as effective molecular targeting agents for treating CRPC.
  • This research opens avenues for novel therapeutic strategies in advanced prostate cancer management.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.9K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.4K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
36.1K